Scarica l'app Stockscreener
0.00
100.00%
-0.0949
AIM ImmunoTech Inc Borsa (AIM) Ultime notizie
AIM ImmunoTech files to sell units, no amount given - MSN
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 - The Globe and Mail
AIM ImmunoTech Inc. Names Ellen Lintal as New Chief Financial Officer - marketscreener.com
AIM ImmunoTech receives NYSE American notice of delisting and appeal - MSN
AIM ImmunoTech appoints Chemerow as an Independent Director - MSN
Aim ImmunoTech CEO Thomas K Equels buys $2,583 in common stock - Investing.com Canada
AIM ImmunoTech begins trading under new ticker AIMI - Investing.com Australia
AIM ImmunoTech begins trading under new ticker AIMI By Investing.com - Investing.com India
AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market - The Manila Times
AIM ImmunoTech Changes Markets: Key Details of AIMI Ticker Switch and Special Meeting - Stock Titan
Aim Immunotech’s COO Peter Rodino III acquires shares for $43 - Investing.com Australia
Aim Immunotech’s COO Peter Rodino III acquires shares for $43 By Investing.com - Investing.com India
AIM ImmunoTech faces NYSE American delisting over low stock price By Investing.com - Investing.com South Africa
AIM ImmunoTech (AIM) Faces Delisting from NYSE American - GuruFocus
AIM ImmunoTech faces NYSE American delisting over low stock price - Investing.com
AIM ImmunoTech announces NYSE American notice of delisting and appeal - TipRanks
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal - GlobeNewswire
NYSE American Suspends AIM ImmunoTech Trading: Company Fighting Delisting Notice - Stock Titan
NYSE American To Commence Delisting Proceedings Against Aim Immunotech Inc - marketscreener.com
NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM) - Business Wire
Dow Tumbles 1,100 Points; US Economy Adds 228,000 Jobs In March - Benzinga
AIM ImmunoTech Inc. (AMEX:AIM) Q4 2024 Earnings Call Transcript - Insider Monkey
AIM ImmunoTech’s Earnings Call: Progress Amid Challenges - TipRanks
AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo
AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strat - GuruFocus
AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... By GuruFocus - Investing.com Canada
AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic - ACCESS Newswire
AIM Immunotech Inc Files For Mixed Shelf Offering Of Up To $100 MillionSEC Filing - MarketScreener
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Earnings Scheduled For March 28, 2025AIM ImmunoTech (AMEX:AIM), China Automotive Systems (NASDAQ:CAAS) - Benzinga
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Earnings Preview For AIM ImmunoTech - Benzinga
AIM ImmunoTech Inc. (AIM) reports earnings - Quartz
AIM Immunotech Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Corporate Update - Marketscreener.com
AIM ImmunoTech Slashes Expenses While Progressing Cancer Trials With AstraZeneca - Stock Titan
AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
Critical Comparison: AIM ImmunoTech (NYSE:AIM) & Windtree Therapeutics (NASDAQ:WINT) - Defense World
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
AIM ImmunoTech Inc. Shares Key Updates on Clinical Trials and Future Plans at Virtual Investor Conference - Nasdaq
AIM ImmunoTech's 5 Game-Changing Programs: Pancreatic Cancer Trial Leads 2025 Strategy - StockTitan
Aim Immunotech CEO Thomas Equels buys $6,730 in stock By Investing.com - Investing.com Canada
Aim Immunotech CEO Thomas Equels buys $6,730 in stock - Investing.com India
What is AIM ImmunoTech Inc (AIM) Stock Return on Shareholders’ Capital? - SETE News
Aim Immunotech CEO Thomas K Equels buys $5,060 in common stock - Investing.com India
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):